FDA approves long-acting injectable HIV regimen for adolescents

The FDA on Tuesday approved the first long-acting HIV treatment regimen for adolescents.
Cabenuva, which includes shots of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen Pharmaceuticals), was first approved for adults last year as a monthly regimen and remains the only long-acting HIV treatment. The FDA recently approved a bimonthly dosing schedule for the injectable regimen, meaning it can be administered as few as six times per year.
The expanded indications means both options will now be available to virologically suppressed adolescents aged 12 years or older who weigh at least 35

The FDA on Tuesday approved the first long-acting HIV treatment regimen for adolescents.
Cabenuva, which includes shots of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen Pharmaceuticals), was first approved for adults last year as a monthly regimen and remains the only long-acting HIV treatment. The FDA recently approved a bimonthly dosing schedule for the injectable regimen, meaning it can be administered as few as six times per year.
The expanded indications means both options will now be available to virologically suppressed adolescents aged 12 years or older who weigh at least 35